4/A: UBS Group AG Corrects Previous Filing on ENDRA Life Sciences Inc. Share Ownership

UBS Group AG files an amended Form 4 to correct a previous filing, stating they never beneficially owned more than 10% of ENDRA Life Sciences Inc. shares due to warrant exercises affecting the total outstanding share count.

Summary

• UBS Group AG filed an amended Form 4 to correct a previous filing made on August 29, 2024.
• The correction clarifies that UBS Group AG, through its subsidiaries UBS Securities LLC and UBS Financial Services Inc., never beneficially owned more than 10% of ENDRA Life Sciences Inc. shares.
• The initial filing was based on an incorrect understanding of the total outstanding common shares issued by ENDRA Life Sciences as of August 27, 2024.
• The correct total outstanding common shares as of August 27, 2024, was 16,932,593 shares, after accounting for certain warrant exercises.
• The corrected filing indicates that the previous Form 4 was erroneous and unnecessary.

Sentiment

Score: 5

Explanation: The document is a correction of a previous filing, indicating a neutral sentiment. The error in the initial filing is a minor negative.

Negatives

• The initial Form 4 filing by UBS Group AG was erroneous, indicating a potential lack of due diligence in determining beneficial ownership.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership of company stock, ensuring transparency in the market.

Stakeholder Impact

• The correction ensures accurate information is available to shareholders regarding the ownership structure of ENDRA Life Sciences Inc.

Key Dates

Keywords

Form 4, UBS Group AG, ENDRA Life Sciences Inc., Beneficial Ownership, Amendment, Share Count, Warrant Exercises